# GT Biopharma, Inc. (GTBP) · Edgar & Edgarette company card

> GT Biopharma (GTBP) reported revenue of $0 million in FY2020, operating margin null against a -3.8% median for pharmaceutical preparations, equity -520% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 109657 · fiscal year ended 2020-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/GTBP) · [JSON](https://www.pops4.com/boards/company/GTBP.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year Infinity%) |
| Net margin | -Infinity% |
| Operating cash flow | −$7M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $5M |
| Long-term debt | — |
| Total assets | $6M |
| Total equity | −$29M |
| Equity ÷ assets | -519.9% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -386.12 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · filed earlier statements no longer to be relied on in the last 12 months; operating cash flow was negative (-$12.9M in FY2025)

## Edgarette's reading

Exposure: revenue $0K (FY2020). Experience: one year on record; operating margin null, down from null. Soundness: equity -519.9% of assets (liabilities exceed assets). Credibility: four or more audited years, moderate weight, marked down from reasonable: on 2026-03-02 the company said earlier statements should no longer be relied on (8-K Item 4.02), and no 10-K has been filed since. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin null against a -3.8% median.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-05-22 ([filing](https://www.sec.gov/Archives/edgar/data/109657/000149315226024913/0001493152-26-024913-index.htm))
- Item 4.02 Earlier statements no longer to be relied on: 1, latest 2026-03-02 ([filing](https://www.sec.gov/Archives/edgar/data/109657/000149315226008442/0001493152-26-008442-index.htm))

## Recent filings

- DEF 14A · filed 2026-10-13 · [filing](https://www.sec.gov/Archives/edgar/data/109657/000149315226046861/0001493152-26-046861-index.htm)
- S-1 · filed 2026-10-09 · [filing](https://www.sec.gov/Archives/edgar/data/109657/000149315226046618/0001493152-26-046618-index.htm)
- 8-K · filed 2026-09-25 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/109657/000149315226044309/0001493152-26-044309-index.htm)
- 8-K · filed 2026-09-21 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modifications to Rights of Security Holders; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/109657/000149315226043562/0001493152-26-043562-index.htm)
- 8-K · filed 2026-09-15 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modifications to Rights of Security Holders; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/109657/000149315226042672/0001493152-26-042672-index.htm)
- 8-K · filed 2026-09-03 · 3.03 Material Modifications to Rights of Security Holders; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/109657/000149315226041333/0001493152-26-041333-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000109657.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=109657

## Cite

POPS4, Edgar & Edgarette: GT Biopharma, Inc. (GTBP) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/GTBP. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2020, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.